Federation Des Caisses Desjardins Du Quebec Monopar Therapeutics Transaction History
Federation Des Caisses Desjardins Du Quebec
- $13.8 Trillion
- Q1 2024
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Monopar Therapeutics stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 80 shares of MNPR stock, worth $58. This represents 0.0% of its overall portfolio holdings.
Number of Shares
80Holding current value
$58% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MNPR
# of Institutions
16Shares Held
390KCall Options Held
0Put Options Held
0-
Israel Englander Millennium Management LLC | New York, Ny192KShares$140,4380.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA45.2KShares$32,9710.0% of portfolio
-
Geode Capital Management, LLC Boston, MA41.2KShares$30,0750.0% of portfolio
-
Hrt Financial LP New York, NY32.1KShares$23,4420.0% of portfolio
-
Gerber, LLC Columbus, OH28KShares$20,4430.02% of portfolio
About Monopar Therapeutics
- Ticker MNPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,725,800
- Market Cap $9.29M
- Description
- Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...